Longeveron Inc. (LGVN) News
Follow Longeveron Inc. (LGVN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Longeveron director Ursula Ungaro resigns from board and committees
Longeveron director Ursula Ungaro resigned immediately from the board and four committees, citing personal health issues.Original SEC Filing: Longeveron Inc. [ LGVN ] - 8-K - Nov. 05, 2026This is an AI-powered summary. I
REGULATION | Nov 05, 2026, 09:03 PM UTC
L
Longeveron’s Laromestrocel Shows Fewer Major Adverse Cardiac Events in Phase 2b Trial
EQUITY | Oct 26, 2026, 01:28 PM UTC
L
Longeveron reports ELPIS II misses primary endpoint; to analyze data, explore strategic options
Longeveron announced ELPIS II topline results showing the Phase 2b trial of laromestrocel in HLHS did not meet its primary endpoint of RVEF improvement at 12 months.Key Highlights:Original SEC Filing: Longeveron Inc. [ L
REGULATION | Sep 23, 2026, 08:04 PM UTC
H
Why Generac Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Shares of Generac Holdings Inc (NYSE: GNRC ) rose sharply in pre-market trading after the company announced a supply agreement with Amazon.com Inc. (NASDAQ: AMZN ) for data center backup generators. Generac and Amazon en
LIVE | Sep 17, 2026, 09:19 AM UTC
H
Longeveron shares plunge after Phase 2b stem-cell trial misses endpoint
Longeveron said its Phase 2b trial of a stem-cell therapy for a pediatric heart condition failed to meet its primary endpoint, sending shares down about 60% to $2.65 in after-hours trading.
EARNINGS | Sep 16, 2026, 10:27 PM UTC
M
Longeveron explores options after laromestrocel misses Phase 2b endpoint
Longeveron said it has begun exploring options to maximize shareholder value after its stem cell therapy laromestrocel failed to meet the primary endpoint in a Phase 2b trial for a heart condition in children.
EARNINGS | Sep 16, 2026, 09:55 PM UTC
M
Longeveron ELPIS II misses HLHS primary endpoint; strategic review starts
Longeveron said its ELPIS II trial in HLHS did not meet the primary RVEF endpoint (LS mean diff −0.7 pts; p=0.8336) and has begun a review of options to maximize shareholder value, including cash conservation. Safety was
EARNINGS | Sep 16, 2026, 09:31 PM UTC
L
Longeveron regains Nasdaq $1.00 minimum bid compliance after 10-day close streak
Longeveron regained compliance with Nasdaq's $1.00 minimum bid requirement following a 10-business-day closing price streak at or above $1.00.Key Highlights:Original SEC Filing: Longeveron Inc. [ LGVN ] - 8-K - Sep. 14,
REGULATION | Sep 14, 2026, 08:26 PM UTC
L
Longeveron to present at H.C. Wainwright 28th Global Investment Conference
Longeveron Inc. said it will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 03, 2026, 01:17 PM UTC
H
U.S. stock futures rise as sanctions and yields weigh
U.S. stock futures advance, with Dow Jones, S&P 500 and Nasdaq 100 futures higher, as Scott Bessent expands sanctions on Iran and 10-year Treasury yields stand at 4.71%.
EARNINGS | Aug 25, 2026, 09:38 AM UTC
M
Longeveron appoints Nirav Jhaveri as chief financial officer
Longeveron appoints Nirav Jhaveri as chief financial officer, while Marie Washburn steps down as CFO and returns to corporate controller.
MNA | Aug 19, 2026, 08:06 PM UTC
L
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX: CANF ) stock moved upwards by 52.0% to $4.52 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. Atlantic International (NASDAQ: ATLN ) shares rose 17
EQUITY | Jul 01, 2026, 12:05 PM UTC